Tiagabine in treatment refractory bipolar disorder: A clinical case series

Bipolar Disorders

Volumn 4, Issue 5, 2002, Pages 283-289

  Suppes, Trisha ^a   Chisholm, Karrie A ^a   Dhavale, Dawn ^b   Frye, Mark A ^b   Altshuler, Lori L ^b   McElroy, Susan L ^c   Keck, Paul E ^c   Nolen, Willem A ^d   Denicoff, Kirk D ^e   Leverich, Gabrielle S ^b,e   Rush, A John ^a   Post, Robert M ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Anticonvulsants; Bipolar disorder; Depression; GABAergic activity; Mania; Seizures; Tiagabine

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; LITHIUM; NEUROLEPTIC AGENT; TIAGABINE; VALPROIC ACID;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EPILEPSY; FEMALE; FOLLOW UP; GABAERGIC TRANSMISSION; HUMAN; INFORMED CONSENT; MALE; MANIC DEPRESSIVE PSYCHOSIS; NAUSEA; PRIORITY JOURNAL; RATING SCALE; REFRACTORY PERIOD; RISK BENEFIT ANALYSIS; SEIZURE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NIPECOTIC ACIDS; PROSPECTIVE STUDIES;

EID: 18644374599     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2002.01201.x     Document Type: Article

References (35)

1. McElroy SL, Keck PE. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48: 539-557.
2. Post RM, Altshuler LL, Frye MA et al. An update on the Stanley Foundation Bipolar Network (SFBN). Bipolar Disorders 2001; 3 (Suppl. 1): 13-14.
3. Petty F. Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? Clin Chem 1994; 40: 296-302.
4. Eckstein-Ludwig U, Fei J, Schwarz W. Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br J Pharmacol 1999; 128: 92-102.
5. Benes FM, Berretta S. GABAergic interneurons. Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25: 1-27.
6. Petty F, Kramer GL, Davis LL. Gamma-aminobutyric acid. In: Goodnick PJ ed. Mania: Clinical and Research Perspectives. Washington DC: American Psychiatric Press, Inc, 1998: 157-169.
7. Schmidt D, Gram L, Brodie M et al. Tiagabine in the treatment of epilepsy: a clinical review with a guide for the prescribing physician. Epilepsy Res 2000; 41: 245-251.
8. Loiseau P. Review of controlled trials of gabitril (tiagabine): a clinician's viewpoint. Curr Pharm Des 2000; 6: 879-900.
9. Meldrum BS, Chapman AG. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 1999; 9 (Suppl. 40): 2-6.
10. Leppik IE, Gram L, Deaton R, Sommerville KW. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999; 33: 235-246.
11. Luer MS, Rhoney DH. Tiagabine: a novel anticonvulsant drug. Ann Pharmacother 1998; 32: 1173-1180.
12. Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three times daily as add-on therapy for refractory partial seizures. Epilepsy Res 1998; 30: 31-40.
13. Knake S, Hamer HM, Schomburg U, Oertel WH, Rosenow F. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 1999; 8: 314-317.
14. Ettinger AB, Bernal OG, Andriola MR et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 1999; 40: 1159-1162.
15. Trinka E, Moroder T, Nagler M, Staffen W, Loscher W, Ladurner G. Clinical and EEG findings in complex partial status epilepticus with tiagabine. Seizure 1999; 8: 41-44.
16. Eckardt KM, Steinhoff BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia 1998; 39: 671-674.
17. Schapel G, Chadwick D. Tiagabine and nonconvulsive status epilepticus. Seizure 1996; 5: 153-156.
18. Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. Am J Psychiatry 1999; 156: 2014-2015.
19. Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998; 10: 181-184.
20. Schaffer LC, Schaffer CB, Howe J. The use of tiagabine in the treatment of patients with refractory bipolar disorder. Fourth International Conference on Bipolar Disorder; June 14-16, 2001; Pittsburgh, Pennsylvania. Bipolar Disorders 2001; 3 (Suppl. 1): Poster Abstract no. 108.
21. Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60: 759-762.
22. Leverich GS, Nolen W, Rush AJ et al. The Stanley Foundation bipolar treatment outcome network. I. Longitudinal methodology. J Affective Disord 2001; 67: 33-44.
23. American Psychiatric Association, ed. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Press, 1994.
24. Suppes T, Leverich GS, Keck PE Jr et al. The Stanley Foundation Bipolar Network: demographics and illness characteristics of the first 261 patients. J Affective Disord 2001; 67: 45-59.
25. McElroy S, Altshuler L, Suppes T et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420-426.
26. Denicoff KD, Leverich GS, Nolen WA, et al. Morbidity in 202 patients followed for one year in the Stanely Foundation Bipolar Network (SFBN). Presented at the Second European Stanley Foundation Conference on Bipolar Disorder, September 21-22, 2000, Amsterdam, The Netherlands.
27. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders - Research Version (SCID-I). New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 1996.
28. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania; reliability, validity, and sensitivity. Br J Psychiatry 1978; 133: 429-435.
29. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986; 18: 65-87.
30. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger JE, Burns CT. The Inventory of Depressive Symptomatology (IDS): preliminary findings. Psychopharmacol Bull 1986; 22: 985-990.
31. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477-486.
32. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modifications of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171.
33. Leverich GS, Post RM. Life charting of affective disorders. CNS Spectrums 1998; 3: 21-37.
34. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder. a placebo-controlled trial of adjunctive therapy. Gabapentin bipolar disorder study group. Bipolar Disorders 2000; 2: 249-255.
35. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614.